Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | 21.47% | -18.55% | 6.56% | 4.48% | -1.44% |
| Total Depreciation and Amortization | -0.79% | -1.04% | -3.75% | -1.09% | -9.70% |
| Total Amortization of Deferred Charges | 0.89% | 0.54% | 0.72% | -10.06% | -0.81% |
| Total Other Non-Cash Items | -56.40% | 121.39% | -7.51% | 18.38% | -23.83% |
| Change in Net Operating Assets | -66.04% | 333.67% | -160.39% | 5.02% | 45.82% |
| Cash from Operations | -15.61% | 39.95% | -41.49% | 10.26% | 1.47% |
| Capital Expenditure | -93.48% | 25.81% | 10.14% | 22.47% | -147.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -93.48% | 25.81% | 10.14% | 22.47% | -147.22% |
| Total Debt Issued | -29.47% | -5.00% | -5.25% | -7.98% | -20.79% |
| Total Debt Repaid | -- | -- | -- | 100.00% | -16,249.75% |
| Issuance of Common Stock | -100.00% | -98.66% | 733.65% | -91.73% | -43.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -32.44% | -75.85% | 187.51% | 206.82% | -114.34% |
| Foreign Exchange rate Adjustments | -6.43% | -235.32% | -76.45% | -220.52% | 72.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.08% | -30.56% | 25.71% | 51.04% | -248.30% |
